If Nature Failed Creating the Perfect Prostate Could Inhibitors ofProteolysis Help

In young man it is working flawlessly and begins deteriorating in the forties, fifties or sixties when some men start to have problems with urinating, a benign prostate hyperplasia (BPH), hematuria and worries about prostate cancer. Rates of diagnosis of prostate cancers is different across the world, with lowest in developing countries, especially in Africa, followed by South and East Asia where it is detected much less frequently than in Europe and in the United States. However, mortality rates are the highest in the developing countries [1-3]. Clearly, advanced prostate cancer treatment available in the medically advanced communities prolongs overall survival in men. For example, decline in prostate cancer mortality in the USA compared with the UK in 19942004 coincided with more frequent PSA screening in the USA and more aggressive treatment of the disease [4]. Nevertheless, National cancer Institute (NCI) on its home page estimates that in 2013 it will be approximately 240,000 new cases of prostate cancer and 30,000 deaths related to this disease [5]. Considering that over 30% of men over the age of fifty have histological evidence of prostate cancer on biopsy and that this percentage increases with age, it seems that mortality rate of prostate cancer is not very high in the USA. So it might be that prostate is not such bad organ after all. However, this disease is unpredictable resulting in the mortality as the consequence of the distant metastases [6] most notably, but not exclusively to the bones. Thus it is not a surprise that NCI lists over 460 clinical studies in prostate cancer. They include predominantly androgen deprivation therapy, radiation and others concentrating mainly on reducing cancer cell growth or cancer cell killing. It raises the question if it is any room for different and novel approach for treatment of prostate cancer and its advanced forms.